List view / Grid view
24 February 2015 | By GBI Research
While drug candidates for Alzheimer’s Disease fail at a much higher rate than the pharmaceutical industry average, the total number of active drugs in the AD treatment pipeline is relatively large at 583, implying a high level of commercial interest, says business intelligence provider GBI Research...
31 October 2014 | By Actinogen Ltd
Actinogen Ltd, an Australian biotechnology company, has acquired Edinburgh BioQuarter spin-out, Corticrine Ltd in a deal facilitated and introduced by Professor Alan Boyd of Boyds...
13 October 2014 | By Probiodrug AG
Probiodrug AG announces the launch of its Initial Public Offering and listing on Euronext Amsterdam...
23 September 2014 | By GlobalData
Eli Lilly’s recent partnership with AstraZeneca to develop oral beta-secretase cleaving enzyme (BACE) inhibitor AZD3293 for Alzheimer’s Disease (AD) is a positive step forward for this challenging treatment market, says an analyst with research and consulting firm GlobalData...
17 July 2014 | By Roche
Roche presented data from two phase II studies investigating whether crenezumab can delay cognitive and functional decline in people with mild-to-moderate Alzheimer’s disease...
15 July 2014 | By Novartis
Novartis announced a collaboration with Banner Alzheimer's Institute on a pioneering clinical study in Alzheimer's disease (AD) prevention...
20 May 2013 | By University of Cambridge
New research establishes nature of malfunction in protein molecules that can lead to onset of dementia...
6 September 2011 | By Evotec AG
Evotec's MAO-B inhibitor in patients with Alzheimer's disease (AD) to be developed...
